Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Ioana Agache¹, Yang Song², Pablo Alonso-Coello^{2

3}, Yasmin Vogel⁴, Claudio Rocha², Ivan Solà², Marilina Santero², Cezmi A Akdis^{5

6}, Mubeccel Akdis⁵, Giorgio Walter Canonica⁷, Tomas Chivato⁸, Stefano Del Giacco⁹, Thomas Eiwegger^{10

11

12}, Wytske Fokkens¹³, Christos Georgalas¹⁴, Philippe Gevaert¹⁵, Claire Hopkins¹⁶, Ludger Klimek¹⁷, Valerie Lund¹⁸, Robert Naclerio¹⁹, Liam O'Mahony²⁰, Susanna Palkonen²¹, Oliver Pfaar²², Jürgen Schwarze²³, Michael B Soyka²⁴, De Yun Wang²⁵, Luo Zhang^{26

27

28}, Carlos Canelo-Aybar^{2

3}, Oscar Palomares²⁹, Marek Jutel^{30

31}

Affiliations

¹ Transylvania University Brasov, Brasov, Romania.
² Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
³ CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
⁴ Furtwangen University, Furtwangen im Schwarzwald, Germany.
⁵ Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
⁶ Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.
⁷ Personalized Medicine Asthma & Allergy Clinic, IRCCS Research Hospital, Humanitas University, Milan, Italy.
⁸ School of Medicine, University CEU San Pablo, Madrid, Spain.
⁹ Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
¹⁰ Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.
¹¹ Department of Immunology, University of Toronto, Toronto, ON, Canada.
¹² Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, Departments of Paediatrics and Immunology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
¹³ Department of Otorhinolaryngology, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands.
¹⁴ Medical School, University of Nicosia, Nicosia, Cyprus.
¹⁵ Department of Otorhinolaryngology, Upper Airway Research Laboratory (URL), Ghent University Hospital, Ghent, Belgium.
¹⁶ Department of ENT, Guy's Hospital, London, UK.
¹⁷ Zentrum für Rhinologie und Allergologie, Wiesbaden, Germany.
¹⁸ Royal National Throat, Nose and Ear Hospital, UCLH, London, UK.
¹⁹ Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, USA.
²⁰ Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.
²¹ European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Brussels, Belgium.
²² Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
²³ Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.
²⁴ Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
²⁵ Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
²⁶ Department of Otolaryngology-Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
²⁷ Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
²⁸ Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.
²⁹ Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.
³⁰ Department of Clinical Immunology, University of Wroclaw, Wroclaw, Poland.
³¹ "ALL-MED" Medical Research Institute, Wroclaw, Poland.

PMID: 33683704
DOI: 10.1111/all.14809

Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Ioana Agache et al. Allergy. 2021 Aug.

. 2021 Aug;76(8):2337-2353.

doi: 10.1111/all.14809. Epub 2021 Mar 24.

Authors

Affiliations

¹ Transylvania University Brasov, Brasov, Romania.
² Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
³ CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
⁴ Furtwangen University, Furtwangen im Schwarzwald, Germany.
⁵ Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
⁶ Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.
⁷ Personalized Medicine Asthma & Allergy Clinic, IRCCS Research Hospital, Humanitas University, Milan, Italy.
⁸ School of Medicine, University CEU San Pablo, Madrid, Spain.
⁹ Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
¹⁰ Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.
¹¹ Department of Immunology, University of Toronto, Toronto, ON, Canada.
¹² Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, Departments of Paediatrics and Immunology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
¹³ Department of Otorhinolaryngology, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands.
¹⁴ Medical School, University of Nicosia, Nicosia, Cyprus.
¹⁵ Department of Otorhinolaryngology, Upper Airway Research Laboratory (URL), Ghent University Hospital, Ghent, Belgium.
¹⁶ Department of ENT, Guy's Hospital, London, UK.
¹⁷ Zentrum für Rhinologie und Allergologie, Wiesbaden, Germany.
¹⁸ Royal National Throat, Nose and Ear Hospital, UCLH, London, UK.
¹⁹ Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, USA.
²⁰ Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.
²¹ European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Brussels, Belgium.
²² Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
²³ Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.
²⁴ Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
²⁵ Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
²⁶ Department of Otolaryngology-Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
²⁷ Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
²⁸ Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.
²⁹ Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.
³⁰ Department of Clinical Immunology, University of Wroclaw, Wroclaw, Poland.
³¹ "ALL-MED" Medical Research Institute, Wroclaw, Poland.

PMID: 33683704
DOI: 10.1111/all.14809

Abstract

This systematic review evaluates the efficacy and safety of biologicals for chronic rhinosinusitis with nasal polyps (CRSwNP) compared with the standard of care. PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CRSwNP-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. RCTs evaluated (dupilumab-2, omalizumab-4, mepolizumab-2, and reslizumab-1) included 1236 adults, with follow-up of 20-64 weeks. Dupilumab reduces the need for surgery (NFS) or oral corticosteroid (OCS) use (RR 0.28; 95% CI 0.20-0.39, moderate certainty) and improves with high certainty smell evaluated with UPSIT score (mean difference (MD) +10.54; 95% CI +9.24 to +11.84) and quality of life (QoL) evaluated with SNOT-22 (MD -19.14; 95% CI -22.80 to -15.47), with fewer treatment-related adverse events (TAEs) (RR 0.95; 95% CI 0.89-1.02, moderate certainty). Omalizumab reduces NFS (RR 0.85; 95% CI 0.78-0.92, high certainty), decreases OCS use (RR 0.38; 95% CI 0.10-1.38, moderate certainty), and improves high certainty smell (MD +3.84; 95% CI +3.64 to +4.04) and QoL (MD -15.65; 95% CI -16.16 to -15.13), with increased TAE (RR 1.73; 95% CI 0.60-5.03, moderate certainty). There is low certainty for mepolizumab reducing NFS (RR 0.78; 95% CI 0.64-0.94) and improving QoL (MD -13.3; 95% CI -23.93 to -2.67) and smell (MD +0.7; 95% CI -0.48 to +1.88), with increased TAEs (RR 1.64; 95% CI 0.41-6.50). The evidence for reslizumab is very uncertain.

Keywords: chronic rhinosinusitis; dupilumab; mepolizumab; omalizumab; reslizumab.

PubMed Disclaimer

Comment in

Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: A network meta-analysis.
Boechat JL, Silva D, Sousa-Pinto B, Delgado L. Boechat JL, et al. Allergy. 2022 Apr;77(4):1299-1306. doi: 10.1111/all.15205. Epub 2022 Jan 12. Allergy. 2022. PMID: 34981835 No abstract available.

References

REFERENCES

1. Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.
1. Bachert C, Marple B, Schlosser RJ, et al. Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020;6(1):86.
1. Canonica GW, Malvezzi L, Blasi F, et al. Severe Asthma Network Italy (SANI). Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947.
1. Bachert C, Zhang N. Medical algorithm: diagnosis and treatment of chronic rhinosinusitis. Allergy. 2020;75(1):240-242.
1. Lourijsen ES, Fokkens WJ, Reitsma S. Direct and indirect costs of adult patients with chronic rhinosinusitis with nasal polyps. Rhinology. 2020;58(3):213-217.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Affiliations

Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Authors

Affiliations

Abstract

Comment in

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical